Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04IXD
|
|||
| Former ID |
DNCL002491
|
|||
| Drug Name |
IPH-2101
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 2 | [1] | |
| Company |
Innate Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | MHC class I NK cell receptor 2DL1 (CD158A) | Target Info | Modulator | [2], [3], [4] |
| MHC class I NK cell receptor 2DL2 (CD158b1) | Target Info | Modulator | [2], [3], [4] | |
| MHC class I NK cell receptor 2DL3 (CD158b2) | Target Info | Modulator | [2], [3], [4] | |
| MHC class I NK cell receptor 2DS1 (CD158h) | Target Info | Modulator | [2], [3], [4] | |
| MHC class I NK cell receptor 2DS2 (CD158j) | Target Info | Modulator | [2], [3], [4] | |
| KEGG Pathway | Antigen processing and presentation | |||
| Natural killer cell mediated cytotoxicity | ||||
| Graft-versus-host disease | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| WikiPathways | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01222286) Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma. U.S. National Institutes of Health. | |||
| REF 2 | Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. | |||
| REF 3 | IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers. Curr Opin Mol Ther. 2010 Dec;12(6):724-33. | |||
| REF 4 | A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.